Effects of calmodulin antagonists on hydrogen-translocating shuttles in perfused rat liver.
The effects of calmodulin antagonists on the capacity of hydrogen-translocating shuttles were studied in the perfused rat liver. The capacity was estimated by measuring the changes in the rate of production of glucose from sorbitol during the oxidation of ethanol [T. Sugano, T. Ohta, A. Tarui, and Y. Miyamae. Am. J. Physiol. 251 (Endocrinol. Metab. 14): E385-E392, 1986]. Thyroxine given to intact rats increased the activity of alpha-glycerophosphate dehydrogenase (alpha-GPD). Glucocorticoid replacement in adrenalectomized rats decreased the activity of the alpha-GPD to values obtained after treatment with PTU. In either thyroxine-treated or steroid-replaced rats, the capacity of hydrogen-translocating shuttles increased markedly. However, N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide (W-7), trifluoperazine, and chlorpromazine inhibited the increased capacity in steroid-replaced rats and had no effect on the increased capacity in thyroxine-treated rats. W-7 inhibited the stimulatory effects of norepinephrine on the capacity of the malate-aspartate shuttle without inhibition of efflux of intracellular Ca2+. The stimulatory effects of vasopressin on the malate-aspartate shuttle were also inhibited by W-7, trifluoperazine, and chlorpromazine. The results suggest that the malate-aspartate shuttle may be regulated by Ca(2+)-calmodulin.
Hamatani
Y
Y
Department of Veterinary Physiology, College of Agriculture, University of Osaka Prefecture, Japan.
Inoue
M
M
Kimura
K
K
Shiota
M
M
Ohta
M
M
Sugano
T
T
D000315:Adrenalectomy; D000409:Alanine / Q000494:pharmacology; D000625:Aminooxyacetic Acid / Q000494:pharmacology; D000818:Animals; D001216:Asparagine / Q000494:pharmacology; D002118:Calcium / Q000378:metabolism; D002147:Calmodulin / Q000037:antagonists & inhibitors*; D002746:Chlorpromazine / Q000494:pharmacology*; D005993:Glycerolphosphate Dehydrogenase / Q000378:metabolism*; D006980:Hyperthyroidism / Q000378:metabolism*; D007037:Hypothyroidism / Q000378:metabolism*; D008099:Liver / Q000187:drug effects / Q000378:metabolism*; D008297:Male; D008930:Mitochondria, Liver / Q000187:drug effects / Q000378:metabolism*; D009243:NAD / Q000378:metabolism*; D010084:Oxidation-Reduction; D010477:Perfusion; D011441:Propylthiouracil / Q000494:pharmacology; D051381:Rats; D011919:Rats, Inbred Strains; D012016:Reference Values; D013012:Sorbitol / Q000494:pharmacology*; D013449:Sulfonamides / Q000494:pharmacology*; D013974:Thyroxine / Q000494:pharmacology*; D014268:Trifluoperazine / Q000494:pharmacology*; D014284:Triiodothyronine / Q000097:blood; D014667:Vasopressins / Q000494:pharmacology
D002147:Calmodulin; D013449:Sulfonamides; D014284:Triiodothyronine; D009243:NAD; D014667:Vasopressins; D000625:Aminooxyacetic Acid; D014268:Trifluoperazine; D013012:Sorbitol; C017967:W 7; D001216:Asparagine; D011441:Propylthiouracil; D005993:Glycerolphosphate Dehydrogenase; D000409:Alanine; D013974:Thyroxine; D002118:Calcium; D002746:Chlorpromazine